Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term follow-up of pelvic peritoneum reconstruction with bladder peritoneum flap after extralevator abdominoperineal excision.

Updates in surgery·2026

Same author

Application of flipped classroom in surgical education: a systematic review and meta-analysis.

Frontiers in medicine·2026

Same author

Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer: A Narrative Review of Incidence and Clinical Risk Factors.

Current oncology (Toronto, Ont.)·2026

Same author

Host genetic variants in the lactose metabolism pathway associated with bifidobacterium abundance have prognostic value for immunotherapy efficacy.

British journal of pharmacology·2026

Same author

Thalidomide-mediated immunomodulation in a patient with <i>IL-10RA</i> deficiency-associated very early-onset inflammatory bowel disease.

Frontiers in immunology·2026

Same author

Development of a recombinase polymerase amplification-based chromogenic assay for rapid detection of <i>Salmonella</i>.

Frontiers in microbiology·2026

Search research articles

Related Experiment Video

Updated: May 21, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

TP53 codon 72 polymorphism and glioma risk: A meta-analysis.

Minghan Shi¹, Ruishan Huang, Chunying Pei

¹Department of Immunology, Harbin Medical University, Harbin 150081, P.R. China.

Oncology Letters

|June 29, 2012

Summary

The TP53 codon 72 polymorphism is not linked to overall glioma risk. However, it is associated with an increased risk of developing high-grade glioma in European populations.

More Related Videos

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Experiment Videos

Last Updated: May 21, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice

Published on: August 12, 2014

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Area of Science:

Genetics
Oncology
Neuroscience

Background:

The TP53 codon 72 polymorphism influences regulatory networks critical for glioma development.
Previous studies on the association between TP53 codon 72 polymorphism and glioma risk have yielded inconsistent findings.
A meta-analysis is needed to clarify the relationship between this polymorphism and glioma risk.

Purpose of the Study:

To conduct a meta-analysis to assess the association between TP53 codon 72 polymorphism and glioma risk.
To investigate potential associations within specific subgroups, such as by tumor grade and geographical location.

Main Methods:

A comprehensive search of PubMed was performed to identify relevant studies.
Data from eight studies, including 2,260 glioma cases and 3,506 controls, were retrieved and pooled.
Statistical analysis, including odds ratios (OR) and 95% confidence intervals (95% CI), was used to evaluate the association.

Main Results:

No significant association was found between TP53 codon 72 polymorphism and overall glioma risk.
A significant association was observed in European patients with high-grade glioma compared to controls.
This association was evident in both dominant and additive models of the TP53 codon 72 polymorphism.

Conclusions:

TP53 codon 72 polymorphism is not a risk factor for glioma in general.
The study suggests a specific association between TP53 codon 72 polymorphism and an elevated risk of high-grade glioma among Europeans.